When and how people recover after an intracerebral hemorrhage

Timing and Outcomes of Recovery After intraCerebral Hemorrhage

This registry will collect detailed, long-term data on adults who have surgery for intracerebral hemorrhage to see if the timing and type of surgical treatment affect recovery and quality of life.

Quick facts

• Study type: Observational
• Enrollment: 500 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Xuanwu Hospital, Beijing (other)
• Locations: 1 site (Beijing)
• Trial ID: NCT07166146 on ClinicalTrials.gov

What this trial studies

The TORCH registry is a prospective, observational cohort enrolling adults with acute, spontaneous supratentorial intracerebral hemorrhage who receive surgical treatment at Xuanwu Hospital. It will collect standardized, longitudinal data on clinical presentation, imaging (CT/CTA), surgical modality (including endoscopic evacuation, minimally invasive surgery with urokinase, and craniotomy), timing of intervention, and functional and quality-of-life outcomes. Eligibility includes age 18–80, baseline mRS ≤1, and defined severity thresholds (NIHSS ≥6 or GCS 5–15); patients with secondary causes of hemorrhage or irreversible coagulopathy are excluded. By comparing outcomes across interventions and timing, the registry aims to produce granular, real-world evidence to guide surgical decision-making.

Who should consider this trial

Good fit: Adults aged 18–80 with an acute primary supratentorial intracerebral hemorrhage who undergo a surgical intervention and have baseline mRS ≤1 and NIHSS ≥6 or GCS 5–15 are ideal candidates.

Not a fit: Patients with secondary causes of intracerebral hemorrhage, irreversible coagulopathy, very limited life expectancy from other illnesses, or those not receiving surgery are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, the registry could identify which surgical approaches and timing are linked to better recovery and quality of life, helping guide future treatment choices.

How similar studies have performed: Previous randomized and observational efforts of minimally invasive and endoscopic hematoma evacuation have shown mixed results—some reduce hematoma volume but have not consistently produced clear functional benefit—so comparative registry data remain valuable and relatively novel.

Eligibility criteria

Inclusion Criteria:

* Subject Age is ≥18 to ≤80 years
* Subject with a Head CT/CTA that demonstrates an acute, spontaneous, primary, supratentorial ICH, assessed via standard of care techniques
* Subject recieving a surgery intervention
* Subject has a NIHSS score ≥ 6 or GCS score 5≤GCS≤15
* Subject has a baseline Modified Rankin Scale (mRS) Score ≤ 1

Exclusion Criteria:

* Secondary intracerebral hemorrhage (with leading cause, e.g., Moyamoya disease, arteriovenous malformation, intracranial aneurysm, tumor, brain trauma)
* Pre-stroke life expectancy \< 1 year for severe comorbidities (e.g., Progressive malignant tumor, severe chronic heart failure \[NYHA: III-IV\], severe chronic obstructive pulmonary disease \[III-IV\], chronic kidney disease requiring hemodialysis)
* Patients with platelet count \< 100,000, INR \> 1.4, or an elevated PT or APTT (reversal of coumadin is permitted but the patient must not require coumadin during the acute hospitalization). Irreversible coagulopathy either due to medical condition or prior to randomization
* Pregnant (positive pregnancy test) or lactating females (likelihood of altered coagulation function associated with the high estrogen/progesterone state)
* Irreversibly impaired brainstem function (bilateral fixed, dilated pupils and extensor motor posturing), GCS less than or equal to 4

Where this trial is running

Beijing

• The Department of Neurosurgery, China International Neuroscience Institute, Xuanwu Hospital, Capital Medical University, — Beijing, China (RECRUITING)

Study contacts

• Study coordinator: Tao Hong, MD

Conditions: Intracerebral Haemorrhage, Intracerebral Hemorrhage